相关实验视频

Updated: Jun 5, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

转移性割敏感前列腺癌的三重疗法:理由和临床证据

Hiroyoshi Suzuki¹, Shusuke Akamatsu², Masaki Shiota³

¹Department of Urology, Toho University Sakura Medical Center, Chiba, Japan.

International journal of urology : official journal of the Japanese Urological Association

|December 9, 2024

概括

结合雄激素受体信号抑制剂 (ARSIs),多塞塔克塞尔和雄激素剥夺疗法 (ADT) 的三重疗法改善了转移性割敏感前列腺癌 (mCSPC) 的结果. 这种方法解决了瘤异质性和耐药性,为mCSPC患者提供了更好的预后.

科学领域:

在瘤学瘤学.
泌尿器科泌尿器科泌尿器科泌尿器科
癌症研究癌症研究

背景情况:

前列腺癌 (PC) 的生长依赖于荷尔蒙,往往进展为转移性割耐药前列腺癌 (mCRPC).
转移性割敏感前列腺癌 (mCSPC) 患者最初对雄激素剥夺疗法 (ADT) 有反应,但最终会产生耐药性.
与mCRPC相关的高死亡率和不良预后凸显了mCSPC未满足的治疗需求.

研究的目的:

审查推理和临床证据支持mCSPC的三重疗法.
探索结合药物与不同作用机制的好处,在mCSPC治疗的早期.
针对晚期前列腺癌的瘤异质性和耐药性.

主要方法:

最近对mCSPC治疗的第三阶段临床试验的审查.
分析临床前研究和关于组合疗法的现实世界数据.
检查前列腺癌中瘤异质性和耐药性机制.

主要成果:

三重疗法 (ARSI,多塞塔塞尔,ADT) 在mCSPC中与多塞塔塞尔加ADT相比显示出更好的预后.
结合ARSI和多塞塔克塞尔,科学证据表明有好处.
早期的组合疗法得到了瘤异质性和耐药性的研究的支持.

结论:

三疗法代表了mCSPC治疗的重大进展.
在mCSPC早期结合ARSI和多塞塔克塞尔是一种合理的方法.
为了改善患者的治疗结果,需要进一步的研究和三重疗法的临床应用.

关键词:

受体信号抑制剂受体信号抑制剂多塞塔克塞尔 (Docetaxel) 是一种药物.转移性割敏感的前列腺癌前列腺癌是前列腺癌.三重疗法是一种三重疗法.

更多相关视频

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...